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Colorectal cancer (CRC) is one of the most intensively studied cancer types, partly 
because of its high prevalence but also because of the existence of its precursor le-
sions, tubular or villous adenomas, and more recently (sessile) serrated adenomas, 
which can be detected endoscopically and removed. The morphological steps in 
the adenoma-carcinoma sequence have been elucidated at a molecular level, which 
has been facilitated by identification of the genes responsible for familial intestinal 
cancer. However, apart from early detection of familial forms of CRC and its use in 
genetic counseling, until recently such detailed molecular knowledge has had little 
impact on clinical management of the disease. 
This has dramatically changed in the last decade. With drugs specifically targeting 
the epidermal growth factor receptor (EGFR) having been shown effective in CRC, 
mechanisms responsible for resistance have been explored. The finding that KRAS 
mutated cancers do not respond to anti-EGFR treatment has had a profound im-
pact on clinical management and on molecular diagnostics of CRC. Additional 
genetic tests for mutations in NRAS, BRAF and PIK3CA contribute to determin-
ing who to treat, and others will follow. New therapies effective in patients with 
advanced CRC are under investigation.
Remaining burning questions for optimal management are which patients will re-
lapse after resection of the primary tumor and which patients will respond to the 
standard 5FU-oxaliplatin adjuvant treatment regimen. Predictive tests to address 
these issues are eagerly awaited. New classifications of CRC, based on molecular 
parameters, are emerging, and we will be confronted with new subtypes of CRC, for 
which the definition is based on combinations of gene expression patterns, chromo-
somal alterations, gene mutations and epigenetic characteristics. This will be instru-
mental in designing new approaches for therapy but will also be translated into mo-
lecular diagnostics. Both will contribute to improved clinical management of CRC.
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Introduction
The face of ‘cutting edge’ medicine is rapidly 
changing. In a recent paper in which they reflect on 
the changes taking place, Stephen Friend and Leroy 
Hood [1] refer to this as P4 medicine: predictive, 
personalized, preventive and participatory. Much of 
this has been brought about by the molecular genet-
ic revolution. It is now possible to sequence a whole 
genome in a matter of days and at an affordable cost. 
In the near future we might all have our personal 
genomic information with us on a smart card, con-
taining the relevant elements of our personal med-
ical history. We will focus here on colorectal cancer 
(CRC), one of the most frequently occurring cancers, 
globally responsible for a high number of cancer-as-
sociated deaths annually [2]. Colorectal cancer is one 
of the most intensively studied cancer types, partly 
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because of its high prevalence but also because of the 
existence of its precursor lesions, tubular or villous 
adenomas and more recently (sessile) serrated ade-
nomas, which can be detected endoscopically and 
removed. Theoretically, removal of these adenomas 
would prevent most cases of CRC from developing. 
Characteristic morphological steps in the evolution of 
these precursor lesions have been elucidated at a mo-
lecular level, and the adenoma-carcinoma sequence, 
as this has become known, is one of the classical ex-
amples of stepwise progression of cancer. Gaining 
this knowledge has been facilitated by the occurrence 
of a variety of forms of familial intestinal cancer, the 
molecular genetic background of which has been 
largely clarified [3]. Apart from early detection of 
familial forms of CRC and its use in genetic coun-
seling, until recently detailed molecular knowledge 
has had little impact on the clinical management of 
CRC. Classical clinico-pathological parameters have 
remained essential factors in determining how a CRC 
patient will be treated. It is the purpose of this paper 
to review how advancing knowledge of the molecular 
events involved in the development of CRC and its 
precursor lesions up to the metastatic stage have in-
fluenced our approach to (early) detection and treat-
ment of this globally widespread disease, which still 
kills half of those who develop it [2]. 
Pathways in the development of colorectal 
cancer
Molecular studies of CRC have elucidated that 
several signaling pathways are involved in its devel-
opment. We now have a fairly detailed insight into 
the main (epi)genetic events involved in colorectal 
carcinogenesis. What has become clear is that CRC 
is not a single disease [3]. The morphological hetero-
geneity, in terms of site, grade and type of the tumor, 
has been expanded by several added layers of mo-
lecular complexity [4-6]. We now realize that CRC 
is a very heterogeneous disease, in terms of clinical 
presentation, likelihood of cure, pattern of extension 
and response to treatment, to name but a few deter-
minants of this heterogeneity. A structured approach 
towards understanding at least parts of this hetero-
geneity follows the molecular pathways involved in 
its genesis. Three main pathway concepts have now 
been developed [7-9], and a fourth has been recently 
added [10]. 
The chromosomal instability pathway
The first elucidated is the classical pathway, of 
which chromosomal instability (CIN) is a hallmark. 
These carcinomas are usually highly aneuploid and 
show striking variation in gene copy number. The 
concept of this pathway was developed by Vogelstein 
in a landmark paper [7], and it is involved in rough-
ly 80% of colorectal carcinomas. The events in this 
pathway are illustrated in Fig. 1. Elucidation of the 
pathway was facilitated through the discovery of the 
adenomatous polyposis coli (APC) gene, the gene re-
sponsible for familial adenomatous polyposis (FAP) 
[11, 12]. APC mutations activate the Wnt signaling 
pathway, which plays a central role in the development 
of CRC, as in about 90% of all CRC cases gene abnor-
malities occur which activate this pathway [13]. Most 
of these are loss of function mutations of APC, but rare 
β-catenin mutations have been reported. The second 
allele of APC is subsequently silenced through muta-
tion, allelic loss or gene promoter methylation. Loss of 
function of the APC protein interferes with phosphor-
ylation of β-catenin, which is then no longer ubiquiti-
nated and fails to be eliminated in the proteasome. 
When β-catenin accumulates, it is translocated to the 
nucleus, where it assumes a transcription factor func-
tion in interaction with LEF/TCF and upregulates the 
expression of genes that promote cell growth (Fig. 2). 
Wnt pathway activation is already present in adeno-
matous polyps, precursor lesions of CRC, and hence 
is considered as an early event in CRC carcinogenesis. 
That colon adenomas are precursor lesions of car-
cinomas was known, long before molecular knowl-
edge started to elucidate the mechanisms involved. 
Over time, the progression of an adenomatous polyp 
into a malignant carcinoma became known as the ad-
Fig. 1. The model of stepwise progression of colorectal cancer as originally proposed by Vogelstein [7]. The histology 
panels show morphological characteristics of the lesion at each step; purported molecular lesions associated with each 
transition are indicated above the arrows. + activating mutation; – inactivating mutation  
Source: World Cancer Report 2014. IARC, WHO press 2014, p. 395. ISBN 978-92-832-0429-9. Published with permission.
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enoma-carcinoma sequence. With the elucidation of 
molecular mechanisms involved, Vogelstein [7] sup-
plemented this concept with molecular data, which 
with the equally well established stepwise progres-
sion concept resulted in the molecular model which 
has become almost a standard approach to address 
molecular carcinogenesis (Fig. 1). 
FAP patients with a germline mutation of APC 
develop hundreds to thousands of adenomatous pol-
yps already at a very young age and have a 100% life-
time risk of the development of CRC. Development 
of neoplastic lesions is not limited to the colorectum: 
neoplasms occur also in the upper intestinal tract 
(stomach, duodenum) and in connective tissue (des-
moid tumors). There is a striking genotype-pheno-
type relationship regarding the clinical characteristics 
of FAP patients. Mutations before codon 157, after 
codon 1595, and in the alternatively spliced region 
of exon 9 are associated with a much lower adenoma 
frequency (attenuated FAP, for a review see 14) and 
also with the occurrence of lesions in the upper gas-
trointestinal tract (duodenum and stomach). In con-
trast, mutations between codons 1250 and 1464 are 
associated with severe polyposis. Mutations after co-
don 1444 are associated with occurrence of desmoid 
tumors [14]. Also in sporadic CRC, which usually de-
velop at advanced age (mostly from the seventh de-
cade on), APC mutations occur but these are somatic, 
not germline [15].
Additional molecular events are activating mu-
tations of KRAS and BRAF in the MAPK pathway. 
Mutations of KRAS are found in around 45% of 
CRC and constitutively activate the MAPK signaling 
pathway (Fig. 3). BRAF, downstream of KRAS in the 
MAPK pathway, is mutated in less than 10% of the 
cases. Mutations in the MAPK pathway also occur in 
NRAS and in phosphoinositide-3-kinase (PIK3) [16]. 
We will come back to this issue in the context of mo-
lecular predictors of response to targeted treatment 
in CRC.
In the classical pathway, loss of function mutations 
of the TP53 gene occur in about 70% of the cases 
with accumulation of the mutated protein in the nu-
cleus (Fig. 4), but as a rule in the progression from 
high-grade adenoma to carcinoma, when also telo-
merase is activated [17], which confers an unlimited 
lifespan on the transformed cells. Activation of the 
TGF-β pathway, which is reflected in the loss of its 
downstream effector SMAD4, is probably involved in 
metastatic progression [18]. 
The classical pathway is associated with FAP and 
germline mutations in the APC gene, but not all pa-
The canonical Wnt signaling pathway
T
T
Fig. 2. The canonical Wnt pathway. In the absence of Wnt β-catenin is phosphorylated by GSK3β and CK1 in the mul-
tiprotein destruction complex (MDC), which contains axin, APC, GSK3β and CK1, and subsequently degraded in the 
proteasome. Binding of Wnt to its receptor Frizzled and the co-receptors LRP5/6 creates a receptor complex. This desta-
bilizes the MDC, as a result of which it no longer phosphorylates β-catenin, the key mediator of the pathway. β-catenin 
is then no longer degraded in the proteasome, accumulates in the cytoplasm, and migrates to the nucleus. Here it forms 
a transcription complex with pygopus (pygo), Bcl-9 and TCF/LEF, which is no longer inhibited by the transcriptional 
repressor groucho (grg). Transcription of proliferation-stimulating target genes, including c-myc and CDK1, ensues 
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tients with polyposis have an APC mutation. Detailed 
analysis of the genome of such patients has led to the 
discovery of the involvement of the MUTYH gene, 
which is involved in base excision repair following ox-
idative damage to DNA [19]. MUTYH polyposis (or 
MAP) to a large extent follows the same sequence of 
events as FAP patients, but MAP patients often have 
fewer polyps, carcinomas appear between the fourth 
and seventh decade, and the lifetime risk for the de-
velopment of CRC is lower than for FAP patients [20].
The microsatellite instability (MIN) pathway
This pathway is responsible for the development 
of hypermutating carcinomas, which in contrast to 
the CIN carcinomas usually show little aneuploidy. 
The prototype of these pathways was discovered in 
the early 1990s while searching for the molecular ge-
netic origins of hereditary non-polyposis colon cancer 
(HNPCC), which is now known as Lynch syndrome 
[21]. A landmark discovery was that Lynch syndrome 
is caused by a mutation in one of the genes encoding 
the proteins involved in mismatch repair (MMR) [22]. 
During DNA replication errors occur, such as single 
base mismatches or deletions and short insertions, 
which are corrected by MMR. A protein complex 
is formed by the proteins involved in MMR which 
binds the mismatch and uses the information from 
the (correct) complementary strand to excise the er-
ror and repair it. When MMR does not function, the 
cells accumulate errors, which occur also in micro-
satellite sequences. These are repeating sequences of 
DNA, mostly 1-6 base pairs in length, which occur 
throughout the genome. MMR deficiency generates 
novel microsatellite sequences, which can be detected 
by a PCR-based assay. In this assay a panel of mi-
crosatellite marker loci, including BAT25, BAT26, 
D2S123, D5346, and D17S250, is used to detect mi-
crosatellite instability (MSI) [23]. When two or more 
markers are unstable, it is called MSI-H(igh); when 
small molecular EGFR inhibitor
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Fig. 3. The MAPK pathway. Normally the pathway is activated by receptor-ligand interaction, upon which the EGF 
receptor dimerizes and phosphorylates a downstream signaling molecule. This finally leads to transcription of genes 
involved in a variety of cellular activities, including proliferation and invasion. Antibodies or small molecules that bind 
to EGFR can inactivate this process. Targeting EGFR is only an effective approach to silence the pathway if there are no 
downstream proteins constitutively activated by mutation (such as KRAS, BRAF or PIK3CA) 
Fig. 4. Immunohistochemical staining of p53 protein in 
a colon carcinoma. Note diffuse strong staining of all nu-
clei, indicative of mutated p53 
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only one marker is instable, it is called MSI-L(ow); 
and when all markers are stable, it is called microsat-
ellite stable (MSS) (Fig. 5). As mismatch repair pro-
teins are easily detectable in routinely processed tis-
sue sections, immunohistochemical detection of loss 
of expression of one of the relevant proteins (MLH1, 
MSH2, MSH6 and PMS2) has become mainstream in 
the detection of mismatch repair and a screening tool 
for the detection of Lynch syndrome [24] (Fig. 5). 
In pathway terms, this MSI-H is equivalent to the 
microsatellite instability (MIN) pathway. Lynch syn-
drome is responsible for about 3% of CRC, but MSI 
occurs in around 12% of sporadic CRC cases. This is 
due to promoter methylation of MLH1, which shuts 
down MLH1 transcription, resulting in deficient 
MMR and MSI-H [25]. 
MSI carcinomas display a relatively high frequen-
cy of BRAF gene mutations. There are other genes 
preferentially mutated, often characterized by mono-
nucleotide tracts in their coding regions, as is the case 
for the TGF-β receptor II gene and the pro-apoptotic 
gene BAX, which are as a consequence frequently 
inactivated in MMR-deficient cancer. The MS status 
has gained quite a bit of clinical interest for sporadic 
CRC lately as mismatch repair deficient carcinomas 
have a better prognosis than mismatch repair com-
petent carcinomas. Microsatellite instability status is 
gradually entering into clinical decision making [26]. 
In the MIN pathway, the development of neoplas-
tic lesions is quite similar to that in the CIN pathway: 
an adenoma-carcinoma sequence. However, cancers 
that arose through this pathway behave differently 
from those in the CIN pathway: they have a better 
prognosis, respond differently to standard chemo-
therapy, have fairly characteristic morphology as they 
are situated in the right colon, are of mucinous or 
medullary histology (Fig. 6), and display a character-
istic lymphocytic infiltrate [27]. 
It had been noted in the The Cancer Genome Atlas 
(TCGA) whole genome sequencing effort for CRC that 
a subgroup of hypermutating carcinomas are not mi-
crosatellite instable. In addition, families were identi-
fied with oligopolyposis and microsatellite stable CRC 
at young age but without APC or MYH mutations. 
This stimulated the search for additional mechanisms 
responsible for a hypermutating state. Recently it was 
found that germline mutations in the proofreading do-
main of two DNA polymerases (POLE and POLD1) 
A
C
B E
D F
Fig. 5. A typical example of mismatch repair deficiency, as reflected in loss of immunohistochemical staining of MLH1. 
A) MLH1 staining. Note absence of staining of tumor cell nuclei whereas normal crypt cells and stromal cells are positive. 
This as a rule goes along with absence of PMS2 staining (panel D), which is absent as it cannot complex with mutated 
MLH1. B) MSH2 staining. Tumor cell nuclei are stained, as for MSH6 (panel C). Panels E and F confirm microsatellite in-
stability as reflected in a shift in the position of the BAT26 microsatellite marker, due to an aberrant number of repetitions 
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are associated with this syndrome [10]. Lack of correc-
tion of mistakes in DNA replication apparently gener-
ates mutations, with a mutator phenotype as a result 
[28]. This syndrome has been called polymerase proof-
reading-associated polyposis (PPAP). 
The CpG island hypermethylation phenotype 
pathway
Hypermethylation of gene promoter associated 
CpG islands, involved in the regulation of transcrip-
tion, is a frequently encountered mechanism respon-
sible for silencing of tumor suppressor genes. If this 
phenomenon occurs genome-wide, it is called CpG 
island hypermethylation phenotype (CIMP) [29]. 
What causes the CIMP phenotype and what exactly 
its consequences are remains elusive. 
Around the turn of the century, it was noted that 
flat non-adenomatous mucosal lesions, notably in 
the right colon, often have a CIMP. These lesions 
occur as a result of abnormal retention of surface 
epithelium due to hyperproliferation and inhibition 
of apoptotic cell loss. They are composed of glands 
with a saw-tooth like appearance (hence the name 
serrated) and were long considered as largely innocu-
ous hyperplastic polyps. More recently it was shown 
that a subtype of them with particular morphology 
has significant malignant potential, and hence these 
are called sessile serrated adenomas or polyps (SSA/P) 
[30]. They resemble (benign) hyperplastic polyps but 
show a more irregular crypt architecture (Fig. 7) and 
occasionally features of dysplasia. SSA/P have been 
associated with increased risk for the development 
of CRC. The extent of the risk has not yet been ad-
equately established, but current evidence suggests 
that it is lower than the risk of progression of tradi-
tional adenomas [31]. Carcinomas with CIMP were 
noted to be associated with serrated precursor lesions, 
and in addition CIMP carcinomas often harbor BRAF 
mutations. Putting CIMP and serrated morphology 
together led to the development of the CIMP path-
way concept [32]. 
The molecular events in the pathway include 
in addition to CIMP mutation of the BRAF gene, 
characteristically the V600E mutation, methyla-
tion of the promoter of a variety of genes (as a re-
A
C D
B
Fig. 6. Morphological heterogeneity of colorectal cancer. Panel A shows complex tubular and serrated architecture with 
moderate cellular atypia, as the cell polarity is still maintained. Panel B shows a mucinous pattern. If this pattern domi-
nates (> 50%), the tumor is called mucinous carcinoma. Panel C shows a pattern characterized by strong stromal reaction 
(for which the term desmoplastic is used) in the presence of moderate numbers of tumor cells). Panel D shows a pattern 
of poorly differentiated cells growing in syncytial sheets, characteristically with diffuse infiltration of tumor infiltrating 
lymphocytes (TIL), known as medullary carcinoma 
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sult of CIMP), and subsequent methylation of the 
MLH1 gene promoter with silencing of the expres-
sion of MLH1 as a result. This is then responsible 
for MMR insufficiency, MSI, and a hypermutating 
state.
It is important to emphasize here that these 
pathway notions constitute a model framework 
which is useful in further defining molecular events 
in colorectal cancer in association with clinical and 
pathological parameters. In reality, a variety of 
subgroups of colorectal cancer exist with molec-
ular characteristics which overlap to a significant 
degree [30]. Recently, several approaches to the 
development of molecular classifications of CRC 
have been published. These not surprisingly show 
significant similarities between each other and they 
also align with some of the pathway characteristics 
[4–6]. These molecular classifications add a layer of 
complexity to the heterogeneity of CRC. Currently, 
efforts are underway to develop a consensus molec-
ular classification in the context of open source col-
laborative genomic data analysis of which the first 
results have already been published [33]. It remains 
to be seen how exactly these molecular classifica-
tions will impact on clinical management of CRC, 
which is still largely determined by classical TNM 
parameters, even though the MS status recently 
has gained importance as a molecular parameter 
to be taken into account in the choice of adjuvant 
treatment of stage II/III CRC and potentially also 
the choice of treatment of metastatic CRC. This 
brings us to the question of whether, and if so how, 
these pathway concepts have impacted on the clin-
ical management of CRC. 
Molecular solutions to problems in the 
management of colorectal cancer?
Understanding disease is what pathology ulti-
mately strives for, but this understanding should 
serve patients through the development of applica-
tions from which they profit. The issue is therefore 
which burning questions in the present modalities of 
care for CRC patients might profit from a molecular 
solution. In this context the following questions are 
relevant:
•  Can molecular pathology provide more efficient 
approaches towards population screening for CRC? 
•  Can molecular tests predict which patients are at 
high risk for development of recurrent disease after 
primary surgery? 
•  Can molecular tests predict which individuals of 
the cohort of patients at high risk for recurrent 
disease most likely will respond to currently used 
adjuvant (chemo) therapy?
•  Can molecular tests predict which patients most 
likely will respond to the available modalities of 
targeted treatment?
Fig. 7. The CpG island methylator phenotype (CIMP) pathway (also known as the serrated pathway) of colorectal car-
cinogenesis. In the pathway, early lesions are characterized by BRAF mutation (typically the V600E mutation) and CIMP. 
Later lesions show mismatch repair deficiency due to hypermethylation of the MLH1 promoter, morphologically char-
acterized by serrated architecture. These lesions are called sessile serrated adenoma. Further progression is a result of 
hypermutability of the genome due to mismatch repair insufficiency and comprises genome alterations also found in the 
classical pathway (Fig. 1) 
Source: Molecular Surgical Pathology. Cheng L, Eble JN (eds.). Springer Verlag 2013; p. 13 (fig. 1.7). Published with permission
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Molecular screening for colorectal cancer 
Colorectal cancer screening programs have risen 
to global prominence, given the high prevalence of 
this disease and the possibility to identify and ade-
quately treat precursor lesions by colonoscopy. The 
standard approach for these screening programs is fe-
cal occult blood testing (FOBT), in order to identify 
a more limited population qualifying for colonoscopy 
in case of a positive FOBT. Fecal occult blood testing 
is relatively sensitive but lacks specificity [34]. A vari-
ety of molecular approaches are under investigation to 
develop more specific tests. Most focus on the detection 
of tumor DNA in fecal matter, looking for tumor-spe-
cific gene alterations such as hypermethylation or spe-
cific mutations. In a laboratory setting such tests have 
shown promising results, but as yet sensitive and specif-
ic molecular tests to detect cancer are not available [35].
Molecular prognostic tests for colorectal cancer
A key problem in the clinical management of most 
cancers is the question of which patients will present 
recurrent disease after initial therapy, which for most 
cancers is surgical removal of the primary tumor, oc-
casionally after neoadjuvant (chemo- and/or radio-)
therapy. The issue is clear: those patients with a high 
likelihood of recurrent disease, which for now means 
stage III and high-risk stage II cases, might be treated 
with adjuvant chemotherapy. Those with a low likeli-
hood of recurrent disease, stage I and low-risk stage II 
patients, should be spared this therapy, which is as-
sociated with significant side effects. Presently used 
criteria used for patient stratification lack accuracy, 
as even among stage I cancers a small proportion will 
relapse and about 30% of stage III patients will not 
relapse [36]. Several prognostic molecular signatures 
have been developed, which potentially would allow 
stratification of patients according to the risk of re-
currence [37-39]. A recent study has independently 
assessed the performance of these signatures in an in-
dependent patient population and concluded that all 
were prognostically significant [40]. Strikingly, how-
ever, they did not use similar gene sets, nor did they 
identify the same patients as high risk. A combina-
tion of these signatures, not surprisingly, performed 
better than any single signature. These data indicate 
that even though finding effective (molecular) ap-
proaches towards identification of high-risk CRC pa-
tients remains urgent, as yet the efficacy of attempts 
to attain this goal remains questionable. 
Molecular tests predictive for response  
to chemotherapy
Of the CRC patients who qualify for adjuvant che-
motherapy (the ‘high-risk’ – based on clinical and 
histopathological criteria – stage II and the stage III 
patients), only about 50% respond [41]. Those that 
do not respond are exposed to the usual side-effects of 
chemotherapy without having any benefit. It would 
therefore be valuable to have (clinical, molecular) pa-
rameters predicting response to this regimen, which 
as a rule consists of a combination of 5-fluorouracil, 
leucovorin and oxaliplatin (known as FOLFOX). 
Some attempts have been made to develop molecular 
tests to this effect, but as yet none are used in daily 
practice due to lack of sensitivity or specificity [42, 
43]. The search therefore remains on for more effec-
tive approaches towards adjuvant treatment as well 
as for tools to predict treatment response.
Molecular markers predictive of a response  
to targeted therapy in colorectal cancer
As stated before, the standard therapy for advanced 
CRC is based on the combination of 5-fluorouracil/
leucovorin/oxaliplatin (FOLFOX). In the last decade, 
evidence was obtained that for a subpopulation of pa-
tients a therapeutic approach addressing the epider-
mal growth factor receptor (EGFR) might be advanta-
geous. Monoclonal antibodies were developed against 
EGFR with some efficacy in CRC. In prospective clin-
ical trials, initial observations were validated, initial-
ly showing a response to cetuximab [44] and subse-
quently also panitumumab [45] but only in patients 
with a KRAS wild type tumor. This finding rapidly 
promoted KRAS mutation testing in CRC to one of 
the most frequently performed tests in molecular pa-
thology laboratories. An important limitation of the 
KRAS mutation status is, however, that it identifies 
(KRAS-mutated) patients who will not respond to an-
ti-EGFR therapy, which eliminates about 40% of the 
non-responders, but of the KRAS-wild type patients 
only about 40% respond. The capacity to effectively 
predict who will respond rather than those patients 
who will not would be an improvement. Assessing the 
mutation status of other genes in the MAPK pathway 
has been investigated [46], and an approach combin-
ing testing of the mutation status of several genes in-
volved in the MAPK pathway effectively increases the 
predictive value. The accuracy of the presently avail-
able test approaches is, however, still far from ideal, 
and the search is on for molecular tests that more accu-
rately predict targeted therapy response [47].
An important issue in this context is therapy resis-
tance. The beneficial effect of anti-EGFR is as a rule 
of short duration because of the development of resis-
tance [48]. Ongoing studies explore the mechanisms 
responsible for this treatment failure [49]. Others 
search for new molecular targets to treat advanced 
colorectal cancer [50].
Concluding remarks
We are not at the end of what has been a fasci-
nating adventure in terms of discovering the details 
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of colorectal carcinogenesis. We have come from 
classical histopathology (including key gross pa-
thology parameters) through a continuously more 
refined TNM classification approach to molecular 
parameters to stratify patients for therapy, befitting 
the specific characteristics of their cancer. We might 
not understand colorectal carcinogenesis completely, 
but our knowledge is much better than it was two 
decades ago. We are in the middle of the develop-
ment of parameters predicting response to available 
targeted therapies, of the development of new ther-
apies targeting elements of the pathways involved in 
colorectal carcinogenesis, and of molecular tests that 
will predict the response to them. Global attempts 
are being made through TCGA project to gain more 
insight into the molecular biology of colorectal (and 
many other) cancers. Pathology plays a key role in 
this development, as much of the knowledge that has 
been gained has been (and still is) based on molecu-
lar studies on tissue samples that pathologists use to 
make a diagnosis. Pathology and pathologists should 
remain in that central position as a partner in a mul-
tidisciplinary effort, along with molecular (cancer) 
biologists, bioinformaticians and (molecular) oncol-
ogists. Eventually, this will improve early detection 
and provide more accurate prediction of (adjuvant) 
treatment need, more efficient drugs, and accurate 
predictors of drug response, from which our patients 
will profit.
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